Top Healthcare Stocks Beyond The Market Rotation Averaging 128% Forward EPS Growth
Aurinia Pharmaceuticals Inc AUPH
$14.88
▼ -0.80%
($-0.12)
Open
$14.80
Prev Close
$15.00
Day Range
$14.36 – $15.25
52W Range
$8.85 – $19.25
Market Cap
$1.91B
P/E (TTM)
6.42
Beta
1.40
EPS (TTM)
$2.17
📋 Company Profile
| Industry | Biotechnology |
| Country | CA |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2001-07-16 |
| Shares Out. | 128,600,000 |
| Website | auriniapharma.com ↗ |
| Phone | 12507442487 |
| Employees | 128 |
| Revenue | $77.7M |
| Gross Profit | $71.2M |
| Net Income | $34.4M |
| Free Cash Flow | $166.6M |
| Total Assets | $724.0M |
| Total Liabilities | $156.4M |
| Equity | $567.6M |
About Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Aurinia Pharmaceuticals Inc is a publicly traded company under the ticker symbol AUPH on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
13 analysts (2026-07-01)